David Krempa Sells 25,000 Shares of Eton Pharmaceuticals (NASDAQ:ETON) Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 25,000 shares of Eton Pharmaceuticals stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $65.07, for a total transaction of $1,626,750.00. Following the sale, the insider owned 37,025 shares in the company, valued at approximately $2,409,216.75. This trade represents a 40.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

David Krempa also recently made the following trade(s):

• On Tuesday, May 26th, David Krempa sold 37,524 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.49, for a total transaction of $1,181,630.76.
• On Wednesday, May 27th, David Krempa sold 19,679 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.47, for a total transaction of $619,298.13.

Eton Pharmaceuticals Stock Down 2.1%

Shares of ETON opened at $63.05 on Wednesday. The company has a quick ratio of 1.30, a current ratio of 1.52 and a debt-to-equity ratio of 0.41. The company has a 50-day moving average price of $43.42 and a two-hundred day moving average price of $31.03. The stock has a market cap of $1.80 billion, a price-to-earnings ratio of 165.92 and a beta of 0.86. Eton Pharmaceuticals, Inc. has a 12 month low of $14.27 and a 12 month high of $66.37.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its earnings results on Thursday, August 13th. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.24. The business had revenue of $37.59 million during the quarter, compared to analysts’ expectations of $27.11 million. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. Equities analysts predict that Eton Pharmaceuticals, Inc. will post 0.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Eton Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Toth Financial Advisory Corp acquired a new position in Eton Pharmaceuticals in the second quarter worth $43,000. Quarry LP bought a new stake in shares of Eton Pharmaceuticals during the third quarter worth $37,000. Persistent Asset Partners Ltd acquired a new stake in shares of Eton Pharmaceuticals in the second quarter valued at $90,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Eton Pharmaceuticals in the fourth quarter valued at about $44,000. Finally, Legal & General Group Plc bought a new position in shares of Eton Pharmaceuticals in the second quarter valued at about $41,000. 27.86% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ETON has been the subject of several recent analyst reports. Craig Hallum increased their price objective on Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Canaccord Genuity Group upped their target price on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a report on Friday, August 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Friday, July 17th. Zacks Research cut shares of Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Finally, B. Riley Financial reissued a “buy” rating and set a $70.00 price target (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. Four research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $67.50.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.